IPO Details
Bidding Dates
09 Oct 25 - 13 Oct 25
Price Range ₹
461 - 485
Total Equity
₹ 0.00Cr
Lot Size
30
Exchange Status
NSE,BSE
IPO Doc
Subscription Rate
Non-Institutional Investor
35.47×
Qualified Institutional Buyers
130.26×
Employees
16.80×
Retail Investors
35.47×
Total subscription Rate
103.90×
IPO Timeline
Offer start
09 Oct 2025
Offer end
13 Oct 2025
Allotment
14 Oct 2025
Refund initiation
15 Oct 2025
Demat transfer
15 Oct 2025
Listing
16 Oct 2025
Offer start
09 Oct 2025
Offer end
13 Oct 2025
Allotment
14 Oct 2025
Refund initiation
15 Oct 2025
Demat transfer
15 Oct 2025
Listing
16 Oct 2025
About Company
Rubicon Research Limited, founded in 1999, is a pharmaceutical formulation company driven by innovation through research and development, with a strong presence in regulated markets, particularly the United States. The company operates two R&D facilities in India and Canada, both inspected by the USFDA (United States Food and Drug Administration), along with two manufacturing plants in India. It is accredited by global regulatory authorities, including the USFDA, WHO-GMP (World Health Organization – Good Manufacturing Practices), and Health Canada. Rubicon’s portfolio features 55 commercialized formulations in the U.S., underscoring its commitment to regulated markets.
Year Founded
06-05-1999
Promotor Details
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 83.2 | 0 |
| Share Capital | 128457540 | 0 |
Project Details
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives - 1612.74cr
- Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by - 3100cr
Objectives
- Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our CompanyFunding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes
Highlights
- Maintains a robust portfolio of commercialized products, with a market share exceeding 25% for seven products in the U.S. market.
- Operates research and development facilities in India and Canada, enabling continuous product innovation and minimizing dependence on third-party developers.
- Has a well-developed U.S. sales and distribution platform through subsidiaries, catering to both branded and non-branded product segments.
- Demonstrates strong regulatory adherence with successful USFDA inspections and approvals from global regulatory authorities.
- Owns two manufacturing plants in India accredited by international regulatory bodies, ensuring high-quality production standards.
Challenges
- The company relies heavily on the U.S. market, making it vulnerable to regulatory changes, pricing pressures, and economic fluctuations in that region.
- Operating in a highly regulated industry, the company faces potential risks from product recalls, inspection failures, or facility shutdowns, which could disrupt operations.
- Despite significant investment in research and development, not all efforts lead to successful, marketable products, posing a risk to revenue growth.
- The pharmaceutical sector is highly competitive, which may pressure profit margins and limit future growth opportunities.
- Fluctuations in foreign exchange rates could negatively impact financial performance, and restrictive debt covenants could lead to financial strain in case of non-compliance.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2025 | 1,44,966.08 | 1,541.26 | 13,436.27 | 13,436.27 | 8.7177 |
| 2021 | 53,825.24 | 507.00 | -168.88 | -168.88 | -1.1103 |
| 2023 | 7,497.04 | 50.70 | 13,436.27 | 13,436.27 | 8.7177 |
| 2022 | 5,595.18 | 50.70 | 13,436.27 | 13,436.27 | 8.7177 |
| 2024 | 1,10,856.35 | 1,520.99 | 18,42,63,900.00 | 18,42,63,900.00 | 1.3072 |
